Pascal Soriot, AstraZeneca CEO (Cole Burston/Bloomberg via Getty Images)
April 29, 2025 06:37 AM EDTUpdated 08:52 AM
China
Pharma
Law

As­traZeneca posts an­oth­er Truqap study fail, says Chi­na im­port tax could triple

Elizabeth Cairns

Senior biopharma journalist

As­traZeneca’s Truqap is 2-for-4 in its piv­otal can­cer tri­als. It said it was shut­ting down a Phase 3 Truqap study in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

TRENDING NOW

FDA de­lays PDU­FA date for small biotech, rais­ing ques­tions about im­pact of agency cuts

Pfiz­er launch­es a new wave of cost cuts, ex­pects $7.7B in to­tal sav­ings through 2027

As­traZeneca, No­var­tis ex­e­cute ‘US for US’ strat­e­gy as phar­ma tar­iffs near

No­var­tis con­tin­ues earn­ings win­ning streak as it rais­es 2025 sales ex­pec­ta­tions

Boehringer’s up­dat­ed re­sults in HER2-mu­tat­ed lung can­cer im­press

sponsored

Rev­o­lu­tion­iz­ing obe­si­ty treat­ment: Could mi­to­chon­dria hold the key to un­lock­ing fat-spe­cif­ic weight loss?

A service from the Financial Times